38 results about "Cytoskeleton" patented technology

The present invention relates to use of expression vectors and other compounds in methods to disrupt the Linker of Nucleoskeleton and Cytoskeleton (LINC) complex, uncoupling the nucleus from its linkage to the cytoskeleton, resulting in amelioration of diseases caused by one or more Lmna mutations, so-called laminopathies. More particularly, the invention relates to the expression of dominant negative SUN domain protein and / or dominant negative KASH domain protein to disrupt, for example, the LINC complex in cardiomyocytes for suppressing disease progression in dilated cardiomyopathy (DCM).

To provide compositions and methods for treating skin wounds, disorders and diseases.SOLUTION: The disclosure relates, in part, to a pharmaceutical composition comprising one or more polynucleotide species suitable for enhancing, increasing, augmenting, and / or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and / or lysyl hydroxylase 3 polypeptide and / or Keratin type I cytoskeletal 17 polypeptide in a subject. The disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.SELECTED DRAWING: Figure 3

The invention belongs to the field of biotechnology and reproductive medicine, and relates to an application of a cytoskeletal regulatory factor ROCK2 in remodeling male reproductive hormone synthesis, the application is to prepare a preparation for regulating male reproductive hormone synthesis, the preparation is a gene silencing preparation, the active component of the preparation is a small interfering RNA molecule aiming at ROCK2, and the active component of the preparation is a small interfering RNA molecule aiming at ROCK2. By inhibiting expression and activity of ROCK2 in a target cell, enrichment of a cortex F-actin network in a cell cortex and formation of a ring structure are promoted, the level of a phosphorylated myosin light chain is up-regulated, and then the targeted transport efficiency of cholesterol in the cell to mitochondria is enhanced. According to the present invention, the structure is complete, the function is complete, the skeleton stability and the hormone synthesis function of the Redis cell are effectively maintained through the specific inhibition of the ROCK2 expression, the technical threshold and the time cost of the drug screening and evaluation are reduced through the established standardized detection system, and the controllability and the safety of the hormone regulation process are ensured.

The invention belongs to the cross technical field of cell engineering, nano-drugs and biological manufacturing, and particularly discloses a drug-loaded vesicle based on denucleated cells as well as a preparation method and application of the drug-loaded vesicle. According to the invention, a cell suspension and a cytoskeleton relaxant are co-incubated to relax an actin skeleton and weaken nucleoplasm connection; then loading the treated cell suspension on a multi-layer discontinuous density gradient centrifugal medium, realizing physical separation of cell nucleuses and cytoplasm through high-speed centrifugation according to buoyancy density difference, and collecting components of a specific interface to obtain high-purity denucleated cells with a complete membrane structure; then co-incubating the denucleated cells and ROS response type lipidosome (co-carrying therapeutic siRNA and a sound-sensitive agent Ce6) prepared in advance, so that the lipidosome is wrapped or anchored by a denucleated cell membrane; finally, the composite system is subjected to extrusion treatment through a microporous membrane, the drug-loaded vesicles uniform in particle size and stable in structure are obtained, and the drug-loaded vesicles are suitable for various application scenes such as anti-tumor treatment and RNA vaccine delivery.

This invention discloses the application of a PDLIM2 gene overexpression viral vector in the preparation of drugs for treating podocyte disease, wherein the nucleotide sequence of the PDLIM2 gene is shown in SEQ ID NO:1. This invention is the first to discover and verify the core role of the PDLIM2 gene in podocyte protection, confirming its significant downregulation in DKD and FSGS disease models, and demonstrating through functional experiments that PDLIM2 overexpression can effectively stabilize the podocyte cytoskeleton, inhibit apoptosis, and reduce proteinuria, thus establishing it as a key target gene for the treatment of podocyte disease. This invention is the first to intervene at the gene level in the core link of podocyte damage—cytoskeleton stability. By specifically upregulating the expression of PDLIM2 in podocytes, it directly enhances their intrinsic cytoskeleton support and anti-damage ability, achieving a fundamental shift in treatment strategy from "symptomatic support" to "causal repair."

This invention discloses the pharmaceutical applications of a P2Y11-specific inhibitor and compositions containing it, belonging to the field of biomedical technology. This invention discloses for the first time the use of NF157 in the preparation of drugs related to the treatment of HD5-induced pathogen infection. In combating pathogen infection, NF157 can specifically inhibit the binding of P2Y11 to HD5, thereby eliminating the role of HD5 in regulating cytoskeleton rearrangement and promoting filopodia formation, thus becoming a key link in interrupting pathogen infection. By preventing the formation of filopodia, NF157 effectively blocks the bacterial capture pathway, showing significant intervention effects on some pathogens that lack adhesion devices and flagella and rely on cellular pseudopodia capture for invasion.

The invention discloses an artificial cell and a preparation method thereof as well as a bionic tissue and a preparation method thereof, an aqueous dispersion of a negative electricity nanometer material is sprayed into an aqueous phase receiving bath containing a cationic polyelectrolyte and a surfactant through a gas-liquid shearing microfluidic technology, and one-step construction of an artificial cell membrane and a cytoskeleton is realized. According to the method, the internal skeleton enhanced artificial cell is constructed in a water phase by a one-step method by utilizing the electrostatic interaction of the negative electricity nano material and the cationic polyelectrolyte, and the method has the characteristics of convenience in preparation and excellent stability. By introducing different functional materials, multifunctional integration of the artificial cell can be realized. Meanwhile, the adhesion inducer is added, so that a bionic tissue can be further constructed, and the bionic tissue integrates excellent mechanical properties of the artificial cells and can bear disturbance to a certain degree without disintegration.

The invention provides a molecular self-assembly integrin patch for regulating and controlling mechanical signals of cells as well as a preparation method and application of the molecular self-assembly integrin patch, and an extracellular matrix (ECM) bionic cell patch is constructed through a molecular self-assembly technology. According to the patch, a laminin-derived integrin binding ligand is extended and self-assembled through an N-terminal aromatic amino acid to form a fibrous nano network, and the patch has controllable nano-scale ligand distribution, network viscoelasticity and stability, and can specifically activate integrin beta1 at the top end of MSC (mesenchymal stem cell), so that a mechanical signal is conducted from a cell membrane to a cell nucleus. The process coordinates cytoskeleton reconstruction, nuclear deformation and chromatin rearrangement, and finally drives the MSC to efficiently differentiate into neuron-like cells under the condition of no exogenous gene or chemical induction, so as to express nerve markers such as TUBB3 and present functional characteristics such as spontaneous calcium transient. The cell patch can be widely applied to nerve regeneration, tissue engineering, disease model construction and intelligent biological material development.

The invention discloses application of mitochondrion Rab32 in preparation of a medicine for treating chronic sleep deprivation and a research method of the mitochondrion Rab32, and belongs to the technical field of biological medicine. A chronic sleep deprivation mouse model is established, the relationship between mitochondria Rab32 and in-vivo protein change of an SD mouse is researched, and the result shows that the mitochondria Rab32 participates in cytoskeleton protein function regulation and control and participates in neuronal synaptic regeneration by anchoring Sptan1 in cells. Rab32 is a key molecule for mediating neuron synaptic regeneration of SD mice and adjusting synaptic plasticity and cognitive impairment, and the research result may provide a new target for treatment of SD-related cognitive impairment in future.

The application relates to the technical field of biomedical engineering, and particularly discloses a method for extracting binary condensate immune signals, which comprises the following steps: screening disease-related high-expression genes by using a disease model, a normal model and a drug treatment model; screening important protein molecules based on the high-expression genes by using a nucleic acid-protein affinity analysis method; constructing a fusion carrier based on cytoskeleton proteins, important protein molecules and green fluorescent protein tracing; and identifying risk genes and possible downstream proteins associated with condensates by spatial omics imaging based on the fusion carrier of the disease model, the normal model and the drug treatment model, and quantifying the condensation process of the condensates. The application reduces the influence of problems such as condensate state destruction and spatial distribution information loss, and accurately realizes in-situ spatial omics imaging and analysis of an immune microenvironment evolution process of a complex disease.

The invention belongs to the field of cell measurement, and discloses a high-precision rod-shaped bacterial cell length measurement method, which comprises the following steps: S101, segmenting an image containing bacterial cells to be measured to obtain a mask image and a flow field image; s102, separating a mask and a flow field of each bacterial cell in the mask image and the flow field image to obtain a mask of a single bacterial cell and a flow field of a single bacterial cell; s103, respectively acquiring a smooth curve skeleton of each bacterial cell based on the mask and the flow field; s104, extending the smooth curve skeleton to the edge of the cell to obtain a cytoskeleton; and S105, calculating the length of the cytoskeleton. The high-precision rod-shaped bacterial cell length measurement method provides a high-precision, rapid and automatic solution for rod-shaped bacterial cell length measurement.

The application discloses a kind of drugs for treating glucocorticoid glaucoma.The application finds by experiment, Rho kinase inhibitor can inhibit RhoA-ROCK signal pathway, destroy glucocorticoid-induced cytoskeleton remodeling and reduce extracellular matrix deposition.At the same time, 10 μM or less concentration, no toxic side effects to cell growth, while significantly inhibiting RhoA-ROCK signal pathway.The experimental results suggest that RKI1447 can change the morphology of trabecular meshwork cells and inhibit cell migration, thereby regulating aqueous humor drainage, reducing intraocular pressure, and thereby treating glucocorticoid glaucoma.The application provides the application of Rho kinase inhibitor RKI1447 in the preparation of glucocorticoid glaucoma drugs.

Cytoskeletal Network Based Computer Device for Predicting Tissue Cell Mechanics

A structurally intact red blood cell membrane, a preparation method therefor and the use thereof. Defining components of a release solution to lyse red blood cells allows for mild conditions, and can release protein components such as hemoglobin inside the red blood cells, remove cell properties thereof, keep the integrity of the cytoskeleton thereof and the activity of surface antigens of the membrane, and retain key blood group antigens on the surface of the red blood cell membrane while keeping the complete structure of the red blood cell membrane, thus reducing the problem of antigenicity reduction caused by fragmentation of the red blood cell membrane. After the red blood cells are lysed, nanoparticles are coupled to the surface of the red blood cell membrane, thus visualizing the agglutination reaction of the red blood cell membrane under the induction of antibodies. Using a fixed procedure to preserve engineered red blood cell biomembranes can effectively avoid damage to the engineered red blood cell biomembrane caused by ice crystals, ensure that the antigenicity of the membranes is not affected, allow for long-term preservation at room temperature, and prolong the shelf life to two years or more.

The application belongs to the technical field of micromanipulation biological modeling, and is based on a cell stretching tensor calculation method of dissipative particle dynamics, and the specific steps are as follows: step 1), a cell membrane model of dissipative particle dynamics is established; step 2), a simulation boundary condition and a type of ensemble integrator are determined; step 3), a cell membrane and a cytoskeleton model are aggregated; step 4), a microneedle penetration experiment platform is built in a simulation environment and the microneedle penetration experiment is started; and step 5), a strain of the cell in a penetration direction is calculated, the microneedle penetration simulation data are processed, finite strain theory is used for analysis and calculation, and a normal strain is output. The method can calculate the internal strain of the cell model under different parameters, and the effectiveness of the method is verified by comparison with the results in a real experiment.

The invention belongs to the technical field of respiratory disease targeted therapy and protein regulation and control, and relates to application of an ACTN2 protein enhancer in preparation of a medicine for preventing, relieving or treating asthma. The key'switch 'effect of the cytoskeleton protein ACTN2 in airway smooth muscle cell (ASMC) phenotype transformation is discovered and confirmed for the first time. The prior art mainly focuses on inflammatory pathways or bronchial relaxation, while the invention reveals that the expression down-regulation of ACTN2 is a key driving factor which causes the conversion of ASC from a resting systolic phenotype to a pathological synthetic phenotype. The discovery provides a brand new therapeutic target for asthma, especially refractory asthma accompanied by severe airway remodeling and hormone resistance.

This invention relates to the field of large-scale adipose-derived stem cell culture technology, and discloses a culture medium and method for promoting the efficient expansion of adipose-derived stem cells. The method includes: seeding adipose-derived stem cells in a serum-free basal culture medium and maintaining a normoxic environment; adding an expansion additive composed of a Rho-associated kinase inhibitor and a redox buffer component; during the window period when the ambient oxygen partial pressure decreases from normoxic to hypoxic, using the Rho-associated kinase inhibitor to relieve cytoskeleton tension to induce a physically relaxed cell membrane; and assisting the redox buffer component in constructing a reducing environment on the cell membrane surface in situ. This invention utilizes the dynamic synergy of membrane tension regulation and oxygen stress shielding to neutralize transient damage caused by sudden changes in ambient oxygen partial pressure, avoid transmembrane receptor conformational inactivation, inhibit premature cell aging at the mechanistic level, and ensure long-term stable expansion of adipose-derived stem cells without the need for heterologous protein protection.

This invention discloses Astragalus polysaccharide, extracted from Astragalus membranaceus. The average molecular weight of this Astragalus polysaccharide is 8-12 kDa, and its monosaccharides are mainly composed of galacturonic acid, glucose, galactose, and arabinose. This Astragalus polysaccharide is a GalA-type acidic polysaccharide that effectively reduces the deposition of immune complexes and the release of pro-inflammatory factors in renal tissue by regulating signaling pathways such as cGAS-STING. Simultaneously, it improves glomerular filtration function by stabilizing the podocyte cytoskeleton structure, exhibiting a synergistic protective therapeutic advantage. This invention also discloses a method for preparing this Astragalus polysaccharide.

The invention provides a method for inducing mesenchymal stem cells to be differentiated into osteogenesis and application, and belongs to the technical field of stem cells. Comprising the following steps: a, preparing magnetic bioactive glass; b, constructing a polydopamine modified pearl powder composite porous hyaluronic acid-silk fibroin peptide scaffold; c, compounding the magnetic bioactive glass with the polydopamine modified pearl powder modified porous hyaluronic acid-silk fibroin peptide scaffold; d, coupling an induction compound to form a scaffold structure; and e, inoculating mesenchymal stem cells on the scaffold structure, pre-culturing, and culturing in an osteogenic induction culture medium to obtain osteoblasts. By constructing a scaffold structure, a suitable mechanical microenvironment is provided for stem cell osteogenic differentiation, cytoskeleton rearrangement is triggered, cell movement is driven, activation of differentiation signals is triggered, bone marrow mesenchymal stem cells are promoted to be differentiated to osteogenesis, and the scaffold has good application value.

The application discloses a cytoskeleton reconstruction detection method, comprising the following steps: acquiring a continuous microscopic image sequence of a cell to be detected within a preset time window, pre-processing the image sequence and extracting a skeleton to obtain cytoskeleton structure data; based on the cytoskeleton structure data, constructing a cytoskeleton network graph at each time point, wherein the cytoskeleton network graph takes skeleton key structure points as nodes and takes skeleton fiber connection relationships as edges to form a time sequence graph structure; for the time sequence graph structure, extracting structure parameters reflecting node connection relationships and path distribution characteristics, and constructing a topological entropy function based on the structure parameters to form a structure dynamics signal; taking the structure dynamics signal as input, performing frequency domain transformation processing thereon to obtain corresponding frequency spectrum distribution characteristics; based on the frequency spectrum distribution characteristics, extracting parameters, and obtaining a cytoskeleton reconstruction judgment index based on the parameters. The application solves the technical problem that the prior art is difficult to capture subtle structure changes in a reconstruction starting stage.

The invention discloses a method for measuring a cell nucleus modulus based on an AFM (atomic force microscope). The method comprises the following steps: extracting a cell nucleus sample, obtaining a needle insertion curve formula by combining a Sneddon contact model and a Maxwell viscoelastic model, measuring separated cell nucleuses by using an atomic force microscope, and processing experimental data by using Matlab. The method has the beneficial effects that a force-distance curve is obtained by measuring separated cell nucleuses by using a probe, and then in combination with a Sneddon contact model and a Maxwell viscoelasticity model, the influence of cell nucleus viscoelasticity and cytoskeleton on cell nucleus modulus and the relationship between the radius of the needle tip and the indentation depth are considered, so that the accuracy of the cell nucleus modulus is improved. According to the method, a formula suitable for measuring the cell nucleus modulus is deduced, the mechanical parameters of the cell nucleus are obtained by using Matlab fitting experimental data, the influence of a cytoskeleton and other organelles on the viscoelastic parameters of the cell nucleus can be avoided in the measurement process by using the measured and separated cell nucleus, and the measurement result is closer to the real parameters of the cell nucleus.

The invention discloses an ultrasonic response type piezoelectric biological membrane as well as a preparation method and application thereof. The piezoelectric biological membrane comprises a carrier, a loaded medicine and cells, the carrier is an ultrasonic response type piezoelectric film, and the surface of the carrier is of a micro-nano topological structure; the medicine is magnesium ions; the cells are bone marrow mesenchymal stem cells; ferroelectric copolymer magnesium salt and an organic solvent are subjected to a quenching coining technology to obtain an ultrasonic response type magnesium-containing micro-nano topological piezoelectric film, and then the ultrasonic response type magnesium-containing micro-nano topological piezoelectric film is combined with the piezoelectric film through biological adhesion to load mesenchymal stem cells. The magnesium ions, the piezoelectric material, the micro-nano linear topological structure and the BMSC form a chemical-physical-biological synergistic effect to jointly stimulate differentiation of the BMSC, meanwhile, release of the magnesium ions is effectively regulated and controlled by utilizing micro-current generated by the piezoelectric material, a cytoskeleton is remodeled under the guidance of the topological structure, a mechanical transduction signal channel is activated, and the differentiation of the BMSC is promoted. Osteogenesis related genes and protein expression are induced, so that the bone regeneration promoting capacity is exerted, and bone defect repair is accelerated.

The present invention relates to a corneal cell culture support comprising graphene and its uses. The graphene-containing support of the present invention is non-toxic to corneal cells, is optimized for the cell proliferation rate, adhesion rate, and survival rate of corneal cells, enhances the expression of corneal cell-specific genes, and can maintain an optimized corneal cell state through cytoskeletal remodeling and mitochondrial activation. Therefore, the corneal cell culture support has the effect of being utilized in cell therapies, implant materials in the field of regenerative medicine, and tissue engineering platforms.

The application provides a high-efficiency induction culture kit of DC cells and an induction culture method thereof, and belongs to the technical field of cell biology. The kit comprises reagent A and reagent B; wherein the reagent A is a GM-CSF solution, an IL-4 solution, an IL-1 beta solution, an AK1 solution, an ACK1 solution, an MLK3 solution, a PLD1 solution, a type II cytoskeleton 1 solution and a type I cytoskeleton 16 solution; and the reagent B comprises a PD-L1 protein solution, a CTLA-4 protein solution, a TIM-3 protein solution, a LAG-3 protein solution, a CD44 protein solution, a CEA protein solution, a neuron-specific enolase solution and a squamous cell carcinoma-associated antigen protein solution. The kit shortens the cell culture time, improves the induction and maturation rate of DC cells and cell activity, and enhances the killing activity of T cells on lung cancer cells.

Provided herein are pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and / or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and / or Lysyl hydroxylase 3 polypeptide and / or Keratin type I cytoskeletal 17 polypeptide in a subject. Also provided herein are pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.

The invention relates to an application of an activity regulating cytoskeleton associated protein (ARC) in an REV nanoparticle vaccine and the vaccine, and belongs to the technical field of animal vaccine preparation, the amino acid sequence of the activity regulating cytoskeleton associated protein (ARC) is shown as SEQ ID NO.3, the nucleotide sequence is shown as SEQ ID NO.4, and the activity regulating cytoskeleton associated protein (ARC) is shown as SEQ ID NO.3. The activity regulation cytoskeleton associated protein is used as a carrier protein in a nanoparticle vaccine, and the nanoparticle vaccine is an REV nanoparticle vaccine. The ARC is used as a carrier in the nanoparticle vaccine for the first time to be self-assembled into nanoparticles, and the nanoparticles can serve as an antigen delivery platform, play a protein-antigen delivery role and stimulate an organism to generate immune response.

The application belongs to the technical field of biological medicine, and particularly relates to application of a flavone small molecule compound in preparation of a drug for regulating WDR1 and / or treating leukemia. The flavone small molecule compound comprises Gambogic amide, Morellic acid, Flavopiridol hydrochloride, Gambogic Acid and / or Methylophiopogonanone B. The application research finds that the flavone small molecule compound such as Gambogic amide can effectively inhibit the activity of acute myeloid leukemia stem cells, and does not damage normal hematopoietic stem cells. The flavone small molecule compound is combined with WDR1 protein specifically expressed in the leukemia stem cells, induces cytoskeleton depolymerization, and further promotes the occurrence of leukemia stem cell apoptosis. The application provides a new direction for prevention and treatment of AML.

The application belongs to the technical field of medicine, and particularly relates to a styrene acetate compound, a preparation method and application thereof. The application provides a styrene acetate compound with a structure shown in formula 1. The styrene acetate compound with the structure shown in formula 1 provided by the application can play a role of inhibiting RAC1 activity by being combined with RAC1 protein, and is suitable for treating diseases related to RAC1 protein, including Alzheimer's disease, atherosclerosis, tumor cell migration and tumor cell invasion, etc. The results of the examples also show that the styrene acetate compound with the structure shown in formula 1 provided by the application can significantly inhibit the formation of cytoskeleton of tumor cells such as breast cancer and gastric cancer, thereby playing a role of inhibiting the migration and invasion activity of tumor cells.

The invention discloses a culture method for improving the regeneration rate of saussurea involucrata tissue culture seedlings, and relates to the technical field of plant tissue culture, and the culture method comprises the following steps: adding a chelating solution containing lanthanum, cerium, citric acid and glycine into an MS culture medium containing a plant growth regulator, inoculating saussurea involucrata explants, and carrying out standing culture under a dark condition to obtain the saussurea involucrata tissue culture seedlings. The callus is loose in structure and is treated by the rare earth chelating liquid; completely immersing the callus treated by the rare earth chelating solution into the slow-release cytoskeleton modified emulsion, carrying out constant-temperature oscillation treatment, and cleaning with a vitamin C solution after the treatment is finished; inoculating the cleaned calluses to a differential culture medium, placing the differential culture medium in a controllable culture container, and performing circulation treatment according to a preset program. According to the invention, the problems of nutrient precipitation and inducer toxicity in tissue culture are solved by constructing an intelligent response type chelating system and a sustained-release microemulsion carrier; and in cooperation with a gradient physical field regulation strategy, mechanical damage and vitrification of cells are avoided.